Hormonal Contraception and HIV-Positive Women: Metabolic Concerns and Management Strategies

Journal of Midwifery and Women's Health

Volumn 53, Issue 4, 2008, Pages 362-375

  Womack, Julie ^a   Richman, Susan ^a   Tien, Phyllis C ^a   Grey, Margaret ^a   Williams, Ann ^a  

^a NONE

Author keywords

glucose; HIV; hormonal contraception; insulin; lipids; metabolic dysregulation; osteoporosis

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CONTRACEPTIVE AGENT; DESOGESTREL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFAVIRENZ; ESTRANE DERIVATIVE; ESTROGEN; GESTAGEN; GESTODENE; GONANE DERIVATIVE; INDINAVIR; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NELFINAVIR; NEVIRAPINE; NORETHISTERONE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; AWARENESS; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; DRUG DOSE REGIMEN; DYSLIPIDEMIA; FEMALE; FEMALE STERILIZATION; FRACTURE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN METABOLISM; INSULIN RESISTANCE; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; VAGINA RING;

ADOLESCENT; ADULT; CONTRACEPTION; CONTRACEPTION BEHAVIOR; CONTRACEPTIVES, ORAL, HORMONAL; FAMILY PLANNING SERVICES; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; LIPID METABOLISM DISORDERS; METABOLIC DISEASES;

EID: 45849132670     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmwh.2008.01.006     Document Type: Article

References (96)

1. Fang C.T., Chang Y.Y., Hsu H.M., Twu S.J., Chen K.T., Lin C.C., et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 100 (2007) 97-105
2. Branson B.M., Handsfield H.H., Lampe M.A., Janssen R.S., Taylor A.W., Lyss S.B., et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 55 (2006) 1-17
3. Kaiser F.F. Fact sheet: Women and HIV/AIDS in the United States. www.kff.org/hivaids/upload/6092-04.pdf [Accessed September 18, 2007]
4. Centers for Disease Control and Prevention Web site. HIV/AIDS surveillance in adolescents and young adults (through 2005). www.cdc.gov/hiv/topics/surveillance/resources/slides/adolescents/index.htm [Accessed February 7, 2008]
5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 30 Suppl 1 (2007) S42-S47
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
7. National Osteoporosis Foundation Web site. Physician's guide: Diagnosis. www.nof.org/physguide/diagnosis.htm [Accessed May 31, 2007]
8. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352 (2005) 48-62
9. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63 (2003) 2555-2574
10. Godsland I.F. The influence of female sex steroids on glucose metabolism and insulin action. J Intern Med Suppl 738 (1996) 1-60
11. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2003 (2004), Centers for Disease Control and Prevention, Atlanta, GA
12. Barkan S.E., Melnick S.L., Preston-Martin S., Weber K., Kalish L.A., Miotti P., et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiol 9 (1998) 117-125
13. Chiao E.Y., Ries K.M., and Sande M.A. AIDS and the elderly. Clin Infect Dis 28 (1999) 740-745
14. United Nations AIDS Programme Web site. UNAIDS/WHO. AIDS epidemic update. http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdf [Accessed January 2, 2007]
15. Mosher W.D., Martinez G.M., Chandra A., Abma J.C., and Willson S.J. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 10 (2004) 1-36
16. Stanwood N.L., Cohn S.E., Heiser J.R., and Pugliese M. Contraception and fertility plans in a cohort of HIV-positive women in care. Contraception 75 (2007) 294-298
17. Massad L.S., Evans C.T., Wilson T.E., Golub E.T., Sanchez-Keeland L., Minkoff H., et al. Contraceptive use among U.S. women with HIV. J Womens Health (Larchmt) 16 (2007) 657-666
18. Crook D., Godsland I.F., Worthington M., Felton C.V., Proudler A.J., and Stevenson J.C. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Am J Obstet Gynecol 169 (1993) 1183-1189
19. Wynn V., and Godsland I. Effects of oral contraceptives on carbohydrate metabolism. J Reprod Med 31 9 Suppl (1986) 892-897
20. Kahn H.S., Curtis K.M., and Marchbanks P.A. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care 26 (2003) 216-225
21. Kim C., Seidel K.W., Begier E.A., and Kwok Y.S. Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 161 (2001) 1766-1771
22. Kjos S.L., Peters R.K., Xiang A., Thomas D., Schaefer U., and Buchanan T.A. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 280 (1998) 533-538
23. Centers for Disease Control and Prevention Web site. HIV/AIDS surveillance report 2002. www.cdc.gov/hiv/topics/surveillance/resources/reports/index.htm [Accessed February 7, 2008]
24. Rowley D., Danel I., Berg C., and Vinicor F. Diabetes and women's health across the life stages. In: Beckles G.L.A., and Thompson-Reid R. (Eds). The reproductive years (2001), US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation, Atlanta, GA
25. Mensah G.A., Mokdad A.H., Ford E.S., Greenlund K.J., and Croft J.B. State of disparities in cardiovascular health in the United States. Circulation 111 (2005) 1233-1241
26. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
27. Silverberg M.J., Gore M.E., French A.L., Gandhi M., Glesby M.J., Kovacs A., et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis 39 (2004) 717-724
28. Grinspoon S.K. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 118 Suppl 2 (2005) 23S-28S
29. Grunfeld C., and Tien P. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis 37 Suppl 2 (2003) S43-S46
30. Kotler D. Challenges to diagnosis of HIV-associated wasting. J Acquir Immune Defic Syndr 37 (2004) S280-S283
31. Dube M.P. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 31 (2000) 1467-1475
32. Noor M.A., Seneviratne T., Aweeka F.T., Lo J.C., Schwarz J.M., Mulligan K., et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS 16 (2002) F1-F8
33. Massip P., Marchou B., Bonnet E., Cuzin L., and Montastruc J.L. Lipodystrophia with protease inhibitors in HIV patients. Therapie 52 (1997) 615
34. Viraben R., and Aquilina C. Indinavir-associated lipodystrophy. AIDS 12 (1998) F37-F39
35. Bacchetti P., Gripshover B., Grunfeld C., Heymsfield S., McCreath H., Osmond D., et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 40 (2005) 121-131
36. Tien P.C., and Grunfeld C. What is HIV-associated lipodystrophy?. Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 17 (2004) 27-32
37. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 42 (2006) 562-571
38. Mulligan K., Anastos K., Justman J., Freeman R., Wichienkuer P., Robison E., et al. Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 38 (2005) 18-22
39. Tien P.C., Cole S.R., Williams C.M., Li R., Justman J.E., Cohen M.H., et al. Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV study. J Acquir Immune Defic Syndr 34 (2003) 461-466
40. Gripshover B., Tien P., Saag M., Osmond D., Bacchetti P., and Grunfeld C. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men (2003), 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA February 10-14
41. Leow M.K., Addy C.L., and Mantzoros C.S. Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 88 (2003) 1961-1976
42. Lichtenstein K.A. Redefining lipodystrophy syndrome: Risks and impact on clinical decision making. J Acquir Immune Defic Syndr 39 (2005) 395-400
43. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab 9 (2001) 413-419
44. Hadigan C., Meigs J.B., Corcoran C., Rietschel P., Piecuch S., Basgoz N., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 1 (2001) 130-139
45. Meininger G., Hadigan C., Laposata M., Brown J., Rabe J., Louca J., et al. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism 51 (2002) 260-266
46. Pittas A.G., Joseph N.A., and Greenberg A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89 (2004) 447-452
47. Kotler D.P. HIV infection and lipodystrophy. Prog Cardiovasc Dis 45 (2003) 269-284
48. Hommes M.J., Romijn J.A., Endert E., Eeftinck Schattenkerk J.K., and Sauerwein H.P. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 6 (1991) 651-656
49. Saag M., Powderly W., Schambelan M., Benson C., Carr A., Currier J., et al. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: Summary of selected trials. Topics HIV Med 10 (2002) 47-51
50. Drechsler H., and Powderly W.G. Switching effective antiretroviral therapy: A review. Clin Infect Dis 35 (2002) 1219-1230
51. Sherer R. HIV, HAART, and hyperlipidemia: Balancing the effects. J Acquir Immune Defic Syndr 34 Suppl 2 (2003) S123-S129
52. Carr A., Samaras K., Chisholm D.J., and Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351 (1998) 1881-1883
53. Tebas P., Yarasheski K., Henry K., Claxton S., Kane E., Bordenave B., et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 20 (2004) 589-594
54. ter Hofstede H.J., Willems H.L., and Koopmans P.P. Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers. J Clin Virol 29 (2004) 44-50
55. Grunfeld C., Kotler D.P., Shigenaga J.K., Doerrler W., Tierney A., Wang J., et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 90 (1991) 154-162
56. Purnell J.Q., Zambon A., Knopp R.H., Pizzuti D.J., Achari R., Leonard J.M., et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14 (2000) 51-57
57. van der Valk M., Kastelein J.J., Murphy R.L., van Leth F., Katlama C., Horban A., et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15 (2001) 2407-2414
58. Negredo E., Ribalta J., Ferre R., Salazar J., Rey-Joly C., Sirera G., et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 18 (2004) 819-821
59. Amiel C., Ostertag A., Slama L., Baudoin C., N'Guyen T., Lajeunie E., et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19 (2004) 402-409
60. Mondy K., and Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 36 Suppl 2 (2003) S101-S105
61. National Osteoporosis Foundation Web site. Fast facts on osteoporosis. www.nof.org/osteoporosis/diseasefacts.htm [Accessed November 26, 2007]
62. McComsey G., Huang J., Woolley I., Young B., Sax P., Gerber M., et al. Fragility fractures in HIV-infected subjects, an area for improvement (2004), 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA February 8-11
63. Kuhne C.A., Heufelder A.E., and Hofbauer L.C. Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res 16 (2001) 2-9
64. Mondy K., Yarasheski K., Powderly W.G., Whyte M., Claxton S., DeMarco D., et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36 (2003) 482-490
65. Carr A., Miller J., Eisman J.A., and Cooper D.A. Osteopenia in HIV-infected men: Association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 15 (2001) 703-709
66. Hsue P.Y., Lo J.C., Franklin A., Bolger A.F., Martin J.N., Deeks S.G., et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109 (2004) 1603-1608
67. Solages A., Vita J.A., Thornton D.J., Murray J., Heeren T., Craven D.E., et al. Endothelial function in HIV-infected persons. Clin Infect Dis 42 (2006) 1325-1332
68. Godsland I.F. Oestrogens and insulin secretion. Diabetologia 48 (2005) 2213-2220
69. Gaspard U., Scheen A., Endrikat J., Buicu C., Lefebvre P., Gerlinger C., et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 67 (2003) 423-429
70. Spellacy W.N. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives. Am J Obstet Gynecol 142 6 Pt 2 (1982) 732-734
71. Ludicke F., Gaspard U.J., Demeyer F., Scheen A., and Lefebvre P. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Contraception 66 (2002) 411-415
72. Godsland I.F., and Crook D. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol 170 5 Pt 2 (1994) 1528-1536
73. Livingstone C., and Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 102 (2002) 151-166
74. Garza-Flores J., de la Cruz D.L., Valles de Bourges V., Sanches-Nincio R., Martinez M., Fuziwara J.L., and Perez-Palacios G. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 44 (1991) 61-71
75. Knopp R.H., LaRosa J.C., and Burkman Jr. R.T. Contraception and dyslipidemia. Am J Obstet Gynecol 168 6 Pt 2 (1993) 1994-2005
76. Bass K.M., Newschaffer C.J., Klag M.J., and Bush T.L. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 153 (1993) 2209-2216
77. Vessey M., Mant J., and Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception 57 (1998) 231-235
78. Bahamondes L., Juliato C.T., Villarreal M., Sobreira-Lima B., Simoes J.A., and dos Santos Fernandes A.M. Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives. Contraception 74 (2006) 259-263
79. Cobb K.L., Kelsey J.L., Sidney S., Ettinger B., and Lewis C.E. Oral contraceptives and bone mineral density in white and black women in CARDIA. Coronary Risk Development in Young Adults. Osteoporos Int 13 (2002) 893-900
80. Federal Drug Agency Web site. Physician information, 2004. www.fda.gov/medwatch/SAFETY/2004/DepoProvera_Label.pdf [Accessed April 9, 2007]
81. Kaunitz A.M. Depo-Provera's black box: Time to reconsider?. Contraception 72 (2005) 165-167
82. Cundy T., Cornish J., Roberts H., and Reid I.R. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol 186 (2002) 978-983
83. Albertazzi P., Bottazzi M., and Steel S.A. Bone mineral density and depot medroxyprogesterone acetate. Contraception 73 (2006) 577-583
84. Ott S.M., Scholes D., LaCroix A.Z., Ichikawa L.E., Yoshida C.K., and Barlow W.E. Effects of contraceptive use on bone biochemical markers in young women. J Clin Endocrinol Metab 86 (2001) 179-185
85. Orr-Walker B.J., Evans M.C., Ames R.W., Clearwater J.M., Cundy T., and Reid I.R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 49 (1998) 615-618
86. Lara-Torre E., Edwards C.P., Perlman S., and Hertweck S.P. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 17 (2004) 17-21
87. Ouellet D., Hsu A., Qian J., Locke C.S., Eason C.J., Cavanaugh J.H., et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 46 (1998) 111-116
88. Mildvan D., Yarrish R., Marshak A., Hutman H.W., McDonough M., Lamson M., et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 29 (2002) 471-477
89. Lamson M., MacGregor T., Riska P., Erickson D., Maxfield P., Rowland L., et al. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin Pharmacol Ther 65 (1999) 137
90. Cohn S.E., Park J.G., Watts D.H., Stek A., Hitti J., Clax P.A., et al. Depo-medroxyprogesterone in women on antiretroviral therapy: Effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 81 (2007) 222-227
91. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16 (2002) 263-272
92. McCann M.F., and Potter L.S. Progestin-only oral contraception: A comprehensive review. Contraception 50 6 Suppl 1 (1994) S1-S195
93. Backman T. Benefit-risk assessment of the levonorgestrel intrauterine system in contraception. Drug Saf 27 (2004) 1185-1204
94. Kayikcioglu F., Gunes M., Ozdegirmenci O., and Haberal A. Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: A 1-year follow-up study. Contraception 73 (2006) 528-531
95. Delvaux T., and Nostlinger C. Reproductive choice for women and men living with HIV: Contraception, abortion and fertility. Reprod Health Matters 15 29 Suppl (2007) 46-66
96. Speroff L., and Fritz M. Clinical gynecologic endocrinology and infertility. 7th edition (2005), Lippincott Williams & Wilkins, Philadelphia